This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Ponesimod for Relapsing-remitting Multiple Sclerosis

< Back

Ponesimod for Relapsing-remitting Multiple Sclerosis


Neurology and Neurosurgery

December 2017

Ponesimod is a drug which works by blocking the signals which allow the body’s immune cells to travel to and damage the nerve cells. By preventing the immune cells from damaging the nerves, it is thought this drug will stop the damage which causes MS ‘relapses’. In clinical trials it has been shown that ponesimod reduces the number of ‘relapses’ in people with MS and reduced the amount of damage to the nerves (measured by brain scans) compared to a placebo.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Ponesimod for Multiple Sclerosis


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts